D. E. Shaw & Co., Inc. Chroma Dex Corp. Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Chroma Dex Corp. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,283,790 shares of CDXC stock, worth $7.88 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,283,790

Previous 1,011,290 26.95%

Holding current value

$7.88 Million

Previous $5.37 Million 64.98%

% of portfolio

0.01%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$5.26 - $8.55 $1.43 Million - $2.33 Million	272,500 Added 26.95%	1,283,790 $8.86 Million
Q4 2024 Feb 14, 2025	BUY	$3.25 - $7.72 $3.11 Million - $7.39 Million	957,665 Added 1785.86%	1,011,290 $5.37 Million
Q3 2024 Nov 14, 2024	BUY	$2.51 - $3.8 $134,598 - $203,775	53,625 New	53,625 $195,000
Q2 2023 Aug 14, 2023	SELL	$1.31 - $1.79 $76,397 - $104,391	-58,319 Reduced 60.74%	37,694 $59,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.19 $89,440 - $132,348	-60,433 Reduced 38.63%	96,013 $146,000
Q4 2022 Feb 14, 2023	BUY	$1.25 - $1.94 $79,892 - $123,993	63,914 Added 69.07%	156,446 $262,000
Q3 2022 Nov 14, 2022	BUY	$1.19 - $2.06 $29,997 - $51,928	25,208 Added 37.44%	92,532 $114,000
Q2 2022 Aug 15, 2022	SELL	$1.59 - $2.7 $28,891 - $49,061	-18,171 Reduced 21.25%	67,324 $112,000
Q1 2022 May 16, 2022	BUY	$2.02 - $3.92 $47,375 - $91,935	23,453 Added 37.8%	85,495 $210,000
Q4 2021 Feb 14, 2022	BUY	$3.74 - $6.7 $56,945 - $102,014	15,226 Added 32.52%	62,042 $232,000
Q3 2021 Nov 15, 2021	SELL	$6.05 - $10.41 $250,082 - $430,307	-41,336 Reduced 46.89%	46,816 $294,000
Q2 2021 Aug 16, 2021	BUY	$6.66 - $10.92 $587,092 - $962,619	88,152 New	88,152 $869,000

Others Institutions Holding CDXC

# of Institutions

149

Shares Held

24.4M

Call Options Held

190K

Put Options Held

14.1K

View Full List

About ChromaDex Corp.

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $420M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

More about CDXC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account